Nimbus Synergies Appoints Nancy Harrison to its Board of Directors to Strengthen its Position in Canadian Health Tech
Nimbus Synergies, investor, partner, and mentor to Canada’s most promising health technology companies, is pleased to announce the appointment of Nancy Harrison to the Board of Directors. Nancy is a nationally recognized life sciences entrepreneur and investor with almost 30 years of experience as an innovator and leader in the sector.
“I am excited to join the Board of Nimbus Synergies and work more closely with a team who is deeply committed to sourcing the most promising investment opportunities and partnering with inspiring health innovators and entrepreneurs to drive impactful health outcomes,” said Nancy Harrison.
Nancy is a Vancouver-based Venture Partner with Amplitude Ventures. She previously spent more than a decade as a Co-Founder and President of MSI Methylation Sciences, growing it from a nascent startup to raising over USD $70M during her tenure. Prior to her accomplishments at MSI, Nancy spent 14 years as a Senior Vice President and Partner with Ventures West Management, BC’s pioneer Venture Capital firm responsible for significant contributions to the BC tech industry. Nancy led the life sciences team, growing its portfolio allocation from zero to over 30 percent of Venture West’s total investments. During her time with Ventures West, the firm grew from approximately $80 million to $750 million. Nancy also serves on a number of other ecosystem Boards for organizations such as adMare BioInnovations, Genome BC’s Industry Innovation Program (I2), and BIOTECanada Emerging Company Advisory Board . Nancy is also a Fellow with Creative Destruction Labs (CDL) – Vancouver.
“Nancy is a well-respected and celebrated champion of Canada’s life sciences sector and has been a significant contributor to its promotion and growth for nearly three decades. Her expertise as both a venture capitalist and a seasoned operator as well as her alignment with our aspirations make her an important addition to our Board of Directors” says Paul Geyer, CEO, Nimbus Synergies. “I look forward to her contributions as we execute on our ambitions to be Canada’s most impactful health technology venture capital firm.”
With an MBA from McGill and an Engineering degree from Queens, Nancy is a recipient of the 2020 Milton Wong Leadership Award from Life Sciences BC, the 2020 PEAK Award for Excellence in Leadership from the Association of Women in Finance, CDL-Vancouver Fellow of the Year in 2019, and has previously been named to the Globe & Mail’s Top 40 under 40 in Canada.
Nancy’s appointment coincides with long-time technology pioneer and thought leader Greg Peet’s retirement from Nimbus’ Board, where he served for the past five years. Greg’s advocacy of the need for increased early-stage capital in British Columbia’s innovation ecosystem was persuasive in establishing Nimbus’ purpose.
“Greg’s passion, commitment, and mentorship to our organization and especially our investment team has been exemplary and instrumental as it has grown and matured over the last few years,” reflected Paul Geyer. “While his insights and contributions will be missed, we wish him the greatest success and fulfillment in his future endeavours.”
ABOUT NIMBUS SYNERGIES
Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.
Original source here.